Detalhe da pesquisa
1.
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
Invest New Drugs
; 38(3): 812-820, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31300967
2.
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.
Ther Adv Med Oncol
; 12: 1758835920926796, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32536979